S‐Allyl‐Mercapto‐Captopril: A Novel Compound in the Treatment of Cohen‐Rosenthal Diabetic Hypertensive Rats
J Clin Hypertens (Greenwich). 2010;12:451–455. ©2010 Wiley Periodicals, Inc. S‐allyl‐mercapto‐captopril (CPSSA) is a conjugate of captopril with allicin, an active principle in garlic with multiple beneficial actions on metabolic syndrome abnormalities, including weight preservation, observed by the...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical hypertension (Greenwich, Conn.) Conn.), 2010-06, Vol.12 (6), p.451-455 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 455 |
|---|---|
| container_issue | 6 |
| container_start_page | 451 |
| container_title | The journal of clinical hypertension (Greenwich, Conn.) |
| container_volume | 12 |
| creator | Younis, Firas Mirelman, David Rabinkov, Aharon Rosenthal, Talma |
| description | J Clin Hypertens (Greenwich). 2010;12:451–455. ©2010 Wiley Periodicals, Inc.
S‐allyl‐mercapto‐captopril (CPSSA) is a conjugate of captopril with allicin, an active principle in garlic with multiple beneficial actions on metabolic syndrome abnormalities, including weight preservation, observed by the authors in fructose‐induced hypertensive hyperinsulinemic rats and in Koletsky rats. The aim of the study was to examine blood pressure (BP) and glucose levels in the Cohen‐Rosenthal Diabetic Hypertensive (CRDH) model as well as to follow their weight preservation. CRDH rats (n=14) were fed the sugar‐rich copper‐free diet essential for the development of diabetes mellitus. Two months later BP and blood glucose levels were measured. CPSSA was diluted in drinking water and administered at a final dose of 53.5 mg/kg/d (n=8). Control rats (n=6) received no drug (vehicle group). In contrast to control group, CPSSA prevented progressive weight gain, without a detectable effect on food and water intake. CPSSA was effective in attenuating systolic and diastolic BP (P |
| doi_str_mv | 10.1111/j.1751-7176.2010.00270.x |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8673246</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JCH270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3870-2a2263296845bb62840a498983e1ac66dfb13596dc3cbd5bb925121f0a98eb0f3</originalsourceid><addsrcrecordid>eNqNUUtOwzAUtBCIQuEKyBdI8SdxYoSQqvApqIBUytpyEoemcuMoTkuz4wickZPgUKhghzfv6c2bsT0DAMRogN05nQ9wGGAvxCEbEOSmCJEQDdY74GAL7Lo-IL7H3KQHDq2dIxRQytE-6BEUcIw4PQD26ePtfah1q129V3Uqq8a4Nu5qVRf6DA7hg1kpDWOzqMyyzGBRwmam4LRWslmosoEmd-BMlY43MdZNZlLDy0ImqilSOGorVTeqtMVKwYls7BHYy6W26vi79sHz9dU0Hnnjx5vbeDj2UhqFyCOSEEYJZ5EfJAkjkY-kzyMeUYVlyliWJ5gGnGUpTZPMrXASYIJzJHmkEpTTPrjY6FbLZKGy1D2sllq4Xy1k3QojC_EXKYuZeDErEbGQEp85gWgjkNbG2lrlWy5GogtCzEXnt-j8Fl0Q4isIsXbUk993b4k_zruF883Ca6FV-29hcRePXEM_AeWMnLY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>S‐Allyl‐Mercapto‐Captopril: A Novel Compound in the Treatment of Cohen‐Rosenthal Diabetic Hypertensive Rats</title><source>Wiley Online Library Journals【Remote access available】</source><source>Wiley-Blackwell Backfiles (Open access)</source><source>MEDLINE</source><source>PubMed</source><source>EZB Electronic Journals Library</source><creator>Younis, Firas ; Mirelman, David ; Rabinkov, Aharon ; Rosenthal, Talma</creator><creatorcontrib>Younis, Firas ; Mirelman, David ; Rabinkov, Aharon ; Rosenthal, Talma</creatorcontrib><description>J Clin Hypertens (Greenwich). 2010;12:451–455. ©2010 Wiley Periodicals, Inc.
S‐allyl‐mercapto‐captopril (CPSSA) is a conjugate of captopril with allicin, an active principle in garlic with multiple beneficial actions on metabolic syndrome abnormalities, including weight preservation, observed by the authors in fructose‐induced hypertensive hyperinsulinemic rats and in Koletsky rats. The aim of the study was to examine blood pressure (BP) and glucose levels in the Cohen‐Rosenthal Diabetic Hypertensive (CRDH) model as well as to follow their weight preservation. CRDH rats (n=14) were fed the sugar‐rich copper‐free diet essential for the development of diabetes mellitus. Two months later BP and blood glucose levels were measured. CPSSA was diluted in drinking water and administered at a final dose of 53.5 mg/kg/d (n=8). Control rats (n=6) received no drug (vehicle group). In contrast to control group, CPSSA prevented progressive weight gain, without a detectable effect on food and water intake. CPSSA was effective in attenuating systolic and diastolic BP (P<0.01) as well as significantly reducing glucose levels (P<0.01). Control rats continued to gain weight, whereas the groups fed CPSSA did not. CPSSA was shown to have additional beneficial effects on improving BP and glucose level, as well as preserving weight gain. The authors conclude that the combined molecule CPSSA integrates the antihypertensive feature of both allicin and captopril, making it a potential antidiabetic and cardiovascular protective agent.</description><identifier>ISSN: 1524-6175</identifier><identifier>EISSN: 1751-7176</identifier><identifier>DOI: 10.1111/j.1751-7176.2010.00270.x</identifier><identifier>PMID: 20591093</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Animals ; Antihypertensive Agents - therapeutic use ; Blood Pressure - drug effects ; Captopril - therapeutic use ; Cysteine ; Diabetes Mellitus, Type 2 - drug therapy ; Diastole - drug effects ; Disulfides ; Hypertension - drug therapy ; Hypoglycemic Agents - therapeutic use ; Journal of the CardioMetabolic Syndrome ; Male ; Rats ; Rats, Inbred SHR ; Sulfinic Acids - therapeutic use ; Systole - drug effects</subject><ispartof>The journal of clinical hypertension (Greenwich, Conn.), 2010-06, Vol.12 (6), p.451-455</ispartof><rights>2010 Wiley Periodicals, Inc.</rights><rights>Copyright 2010 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3870-2a2263296845bb62840a498983e1ac66dfb13596dc3cbd5bb925121f0a98eb0f3</citedby><cites>FETCH-LOGICAL-c3870-2a2263296845bb62840a498983e1ac66dfb13596dc3cbd5bb925121f0a98eb0f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673246/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673246/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1416,1432,27922,27923,45572,45573,46407,46831,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20591093$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Younis, Firas</creatorcontrib><creatorcontrib>Mirelman, David</creatorcontrib><creatorcontrib>Rabinkov, Aharon</creatorcontrib><creatorcontrib>Rosenthal, Talma</creatorcontrib><title>S‐Allyl‐Mercapto‐Captopril: A Novel Compound in the Treatment of Cohen‐Rosenthal Diabetic Hypertensive Rats</title><title>The journal of clinical hypertension (Greenwich, Conn.)</title><addtitle>J Clin Hypertens (Greenwich)</addtitle><description>J Clin Hypertens (Greenwich). 2010;12:451–455. ©2010 Wiley Periodicals, Inc.
S‐allyl‐mercapto‐captopril (CPSSA) is a conjugate of captopril with allicin, an active principle in garlic with multiple beneficial actions on metabolic syndrome abnormalities, including weight preservation, observed by the authors in fructose‐induced hypertensive hyperinsulinemic rats and in Koletsky rats. The aim of the study was to examine blood pressure (BP) and glucose levels in the Cohen‐Rosenthal Diabetic Hypertensive (CRDH) model as well as to follow their weight preservation. CRDH rats (n=14) were fed the sugar‐rich copper‐free diet essential for the development of diabetes mellitus. Two months later BP and blood glucose levels were measured. CPSSA was diluted in drinking water and administered at a final dose of 53.5 mg/kg/d (n=8). Control rats (n=6) received no drug (vehicle group). In contrast to control group, CPSSA prevented progressive weight gain, without a detectable effect on food and water intake. CPSSA was effective in attenuating systolic and diastolic BP (P<0.01) as well as significantly reducing glucose levels (P<0.01). Control rats continued to gain weight, whereas the groups fed CPSSA did not. CPSSA was shown to have additional beneficial effects on improving BP and glucose level, as well as preserving weight gain. The authors conclude that the combined molecule CPSSA integrates the antihypertensive feature of both allicin and captopril, making it a potential antidiabetic and cardiovascular protective agent.</description><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Animals</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Blood Pressure - drug effects</subject><subject>Captopril - therapeutic use</subject><subject>Cysteine</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diastole - drug effects</subject><subject>Disulfides</subject><subject>Hypertension - drug therapy</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Journal of the CardioMetabolic Syndrome</subject><subject>Male</subject><subject>Rats</subject><subject>Rats, Inbred SHR</subject><subject>Sulfinic Acids - therapeutic use</subject><subject>Systole - drug effects</subject><issn>1524-6175</issn><issn>1751-7176</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUUtOwzAUtBCIQuEKyBdI8SdxYoSQqvApqIBUytpyEoemcuMoTkuz4wickZPgUKhghzfv6c2bsT0DAMRogN05nQ9wGGAvxCEbEOSmCJEQDdY74GAL7Lo-IL7H3KQHDq2dIxRQytE-6BEUcIw4PQD26ePtfah1q129V3Uqq8a4Nu5qVRf6DA7hg1kpDWOzqMyyzGBRwmam4LRWslmosoEmd-BMlY43MdZNZlLDy0ImqilSOGorVTeqtMVKwYls7BHYy6W26vi79sHz9dU0Hnnjx5vbeDj2UhqFyCOSEEYJZ5EfJAkjkY-kzyMeUYVlyliWJ5gGnGUpTZPMrXASYIJzJHmkEpTTPrjY6FbLZKGy1D2sllq4Xy1k3QojC_EXKYuZeDErEbGQEp85gWgjkNbG2lrlWy5GogtCzEXnt-j8Fl0Q4isIsXbUk993b4k_zruF883Ca6FV-29hcRePXEM_AeWMnLY</recordid><startdate>201006</startdate><enddate>201006</enddate><creator>Younis, Firas</creator><creator>Mirelman, David</creator><creator>Rabinkov, Aharon</creator><creator>Rosenthal, Talma</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>201006</creationdate><title>S‐Allyl‐Mercapto‐Captopril: A Novel Compound in the Treatment of Cohen‐Rosenthal Diabetic Hypertensive Rats</title><author>Younis, Firas ; Mirelman, David ; Rabinkov, Aharon ; Rosenthal, Talma</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3870-2a2263296845bb62840a498983e1ac66dfb13596dc3cbd5bb925121f0a98eb0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Animals</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Blood Pressure - drug effects</topic><topic>Captopril - therapeutic use</topic><topic>Cysteine</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diastole - drug effects</topic><topic>Disulfides</topic><topic>Hypertension - drug therapy</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Journal of the CardioMetabolic Syndrome</topic><topic>Male</topic><topic>Rats</topic><topic>Rats, Inbred SHR</topic><topic>Sulfinic Acids - therapeutic use</topic><topic>Systole - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Younis, Firas</creatorcontrib><creatorcontrib>Mirelman, David</creatorcontrib><creatorcontrib>Rabinkov, Aharon</creatorcontrib><creatorcontrib>Rosenthal, Talma</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Younis, Firas</au><au>Mirelman, David</au><au>Rabinkov, Aharon</au><au>Rosenthal, Talma</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>S‐Allyl‐Mercapto‐Captopril: A Novel Compound in the Treatment of Cohen‐Rosenthal Diabetic Hypertensive Rats</atitle><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle><addtitle>J Clin Hypertens (Greenwich)</addtitle><date>2010-06</date><risdate>2010</risdate><volume>12</volume><issue>6</issue><spage>451</spage><epage>455</epage><pages>451-455</pages><issn>1524-6175</issn><eissn>1751-7176</eissn><abstract>J Clin Hypertens (Greenwich). 2010;12:451–455. ©2010 Wiley Periodicals, Inc.
S‐allyl‐mercapto‐captopril (CPSSA) is a conjugate of captopril with allicin, an active principle in garlic with multiple beneficial actions on metabolic syndrome abnormalities, including weight preservation, observed by the authors in fructose‐induced hypertensive hyperinsulinemic rats and in Koletsky rats. The aim of the study was to examine blood pressure (BP) and glucose levels in the Cohen‐Rosenthal Diabetic Hypertensive (CRDH) model as well as to follow their weight preservation. CRDH rats (n=14) were fed the sugar‐rich copper‐free diet essential for the development of diabetes mellitus. Two months later BP and blood glucose levels were measured. CPSSA was diluted in drinking water and administered at a final dose of 53.5 mg/kg/d (n=8). Control rats (n=6) received no drug (vehicle group). In contrast to control group, CPSSA prevented progressive weight gain, without a detectable effect on food and water intake. CPSSA was effective in attenuating systolic and diastolic BP (P<0.01) as well as significantly reducing glucose levels (P<0.01). Control rats continued to gain weight, whereas the groups fed CPSSA did not. CPSSA was shown to have additional beneficial effects on improving BP and glucose level, as well as preserving weight gain. The authors conclude that the combined molecule CPSSA integrates the antihypertensive feature of both allicin and captopril, making it a potential antidiabetic and cardiovascular protective agent.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20591093</pmid><doi>10.1111/j.1751-7176.2010.00270.x</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1524-6175 |
| ispartof | The journal of clinical hypertension (Greenwich, Conn.), 2010-06, Vol.12 (6), p.451-455 |
| issn | 1524-6175 1751-7176 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8673246 |
| source | Wiley Online Library Journals【Remote access available】; Wiley-Blackwell Backfiles (Open access); MEDLINE; PubMed; EZB Electronic Journals Library |
| subjects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use Animals Antihypertensive Agents - therapeutic use Blood Pressure - drug effects Captopril - therapeutic use Cysteine Diabetes Mellitus, Type 2 - drug therapy Diastole - drug effects Disulfides Hypertension - drug therapy Hypoglycemic Agents - therapeutic use Journal of the CardioMetabolic Syndrome Male Rats Rats, Inbred SHR Sulfinic Acids - therapeutic use Systole - drug effects |
| title | S‐Allyl‐Mercapto‐Captopril: A Novel Compound in the Treatment of Cohen‐Rosenthal Diabetic Hypertensive Rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T14%3A35%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=S%E2%80%90Allyl%E2%80%90Mercapto%E2%80%90Captopril:%20A%20Novel%20Compound%20in%20the%20Treatment%20of%20Cohen%E2%80%90Rosenthal%20Diabetic%20Hypertensive%20Rats&rft.jtitle=The%20journal%20of%20clinical%20hypertension%20(Greenwich,%20Conn.)&rft.au=Younis,%20Firas&rft.date=2010-06&rft.volume=12&rft.issue=6&rft.spage=451&rft.epage=455&rft.pages=451-455&rft.issn=1524-6175&rft.eissn=1751-7176&rft_id=info:doi/10.1111/j.1751-7176.2010.00270.x&rft_dat=%3Cwiley_pubme%3EJCH270%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/20591093&rfr_iscdi=true |